SCHEMBL6428012

SCHEMBL6428012

O=c1c2cc(OS(=O)(=O)C(F)(F)F)ccc2n2cnnc2n1Cc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 1/20 0.40
NPSR1 Q6W5P4 3/20 0.38
ALDH1A1 P00352 3/20 0.38
HPGD P15428 2/20 0.38
KDM4E B2RXH2 2/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
PKM P14618 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HIF1A Q16665 1/20 0.38
HTT P42858 1/20 0.37
F11 P03951 2/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PLA2G2A P14555 5/20 0.35
PLA2G1B P04054 1/20 0.35
SRC P12931 1/20 0.34
PTGS1 P23219 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6246632 0.90 MMP13 (0.38) NPSR1ALDH1A1KDM4EGAAMAPT
SCHEMBL6396503 0.86 MAPK8 (0.38) NPSR1ALDH1A1KDM4EMAPTPKM
SCHEMBL6395824 0.79 PLA2G2A (0.46) PLK1NPSR1ALDH1A1HPGDKDM4E
SCHEMBL6850020 0.79 MEN1 (0.48) PLK1NPSR1ALDH1A1HPGDKDM4E
SCHEMBL6215775 0.77 MMP13 (0.47) PLK1NPSR1ALDH1A1HPGDKDM4E
SCHEMBL6229879 0.75 MMP13 (0.55) PLK1NPSR1ALDH1A1HPGDKDM4E
SCHEMBL6233774 0.74 MMP13 (0.52) KDM4E
SCHEMBL6856148 0.73 PLK1 (0.52) PLK1NPSR1KDM4EGAAMAPT
SCHEMBL6212989 0.72 MMP13 (0.54) ALDH1A1MAPTKMT2A
SCHEMBL7415598 0.72 ALDH1A1 (0.57) PLK1NPSR1ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6962922-B2 Alkynylated quinazoline compounds WARNER-LAMBERT COMPANY LLC (US) 2005-11-08 US disclosed
US-20050245548-A1 Alkynylated fused ring pyrimidine compounds GAUDILLIERE BERNARD 2005-11-03 US disclosed
US-20050004126-A1 Method of determining potential allosterically-binding matrix metalloproteinase inhibitors ANDRIANJARA CHARLES (FR) 2005-01-06 US disclosed
US-20030130278-A1 Alkynylated fused ring pyrimidine compounds GAUDILLIERE BERNARD (FR) 2003-07-10 US disclosed
US-20030078276-A1 Matrix metalloproteinase inhibitors ANDRIANJARA CHARLES (FR) 2003-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004126-A1 Method of determining potential allosterically-binding matrix metalloproteinase inhibitors MMP13, MMP12, MMP25 PLK1 1942/4885NPSR1 3566/4885ALDH1A1 4241/4885
US-20030078276-A1 Matrix metalloproteinase inhibitors MMP13, MMP25, MMP12 PLK1 1994/4885NPSR1 3086/4885ALDH1A1 3754/4885
US-20030130278-A1 Alkynylated fused ring pyrimidine compounds MMP13, TIMP3, MMP3 PLK1 4434/4885NPSR1 226/4885ALDH1A1 1473/4885
US-20050245548-A1 Alkynylated fused ring pyrimidine compounds MMP13, TIMP3, MMP3 PLK1 4073/4885NPSR1 201/4885ALDH1A1 1193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.